tiprankstipranks
Trending News
More News >

Palisade Bio initiated with a Buy at Brookline

Brookline initiated coverage of Palisade Bio (PALI) with a Buy rating and $38 price target Palisade Bio is advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, the analyst noted.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1